Perseus Proteomics Inc.
Research Perseus Proteomics Inc. (4882.T) on Bullrun: market cap JPY 2.78B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4882.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyJPY
- Market capJPY 2.78B
- Financial periodFY2026
- RevenueJPY 135.51M
- Revenue growth12.6%
- Net income-JPY 718.11M
- Free cash flow-JPY 663.28M
- Gross margin85.7%
Valuation Snapshot
latest market cap is JPY 2.78B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 135.51M | -JPY 718.11M | -JPY 663.28M | 85.7% | -48.17 | JPY 1.52B | n/a | JPY 1.22B |
| FY2025 | JPY 120.38M | -JPY 904.80M | -JPY 794.64M | 86.4% | -63.41 | JPY 1.67B | n/a | JPY 1.43B |
| FY2024 | JPY 100.40M | -JPY 1.10B | -JPY 992.87M | 87.3% | -93.69 | JPY 1.54B | n/a | JPY 1.40B |
| FY2023 | JPY 94.20M | -JPY 787.00M | -JPY 734.82M | 91.9% | -66.93 | JPY 2.44B | n/a | JPY 2.40B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 2.78B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Perseus Proteomics Inc.
Perseus Proteomics Inc., a drug discovery biotech venture company, develops and sells antibody-based pharmaceuticals and research reagents for cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Perseus Proteomics Inc.'s market cap?
Perseus Proteomics Inc.'s market capitalization is JPY 2.78B.
What does Perseus Proteomics Inc. do?
Perseus Proteomics Inc., a drug discovery biotech venture company, develops and sells antibody-based pharmaceuticals and research reagents for cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products.